The research paper titled “Allogenic Human Mesenchymal Stem Cell Infusions for Aging Frailty” was published in the Journal of Gerontology: Medical Sciences in 2017. The study aimed to investigate the safety and efficacy of allogenic human mesenchymal stem cell (allo-hMSC) infusions in patients with aging frailty.

Aging frailty is a common condition among older adults and is characterized by a decline in physical and cognitive functions, increased susceptibility to diseases, and a higher risk of mortality. Mesenchymal stem cells have been suggested as a potential therapy for aging frailty due to their regenerative properties and ability to modulate the immune system.

The study enrolled 15 participants aged 60 to 95 years who met the criteria for aging frailty. The participants received a single intravenous infusion of allo-hMSCs. The primary outcome was safety, and the secondary outcomes were changes in physical performance, cognitive function, quality of life, and inflammation markers. The participants were followed up for six months after the infusion.

The results of the study showed that allo-hMSC infusions were safe and well-tolerated, with no serious adverse events reported during the follow-up period. The participants showed significant improvements in physical performance, as measured by the Short Physical Performance Battery and the 6-minute walk test. The study also showed improvements in cognitive function, quality of life, and inflammation markers.

The findings of this study suggest that allo-hMSC infusions may be a safe and effective therapy for aging frailty.

This study provides evidence that allo-hMSC infusions may be a promising therapy for aging frailty. The findings of this study have significant implications for the management of aging frailty and suggest a potential new approach for improving the health and quality of life of older adults.